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Abstract
Background: Francisella tularensis is a facultative intracellular bacterial pathogen and the etiological agent of tularemia. The
subspecies F. tularensis tularensis is especially virulent for humans when inhaled and respiratory tularemia is associated with
high mortality if not promptly treated. A live vaccine strain (LVS) derived from the less virulent holarctica subspecies confers
incomplete protection against aerosol challenge with subsp. tularensis. Moreover, correlates of protection have not been
established for LVS.
Methodology/Principal Findings: In the present study we compare molecular immune responses elicited by LVS and two
defined deletion mutants of clinical subsp. tularensis strain, SCHU S4, that confer enhanced protection in a mouse model.
BALB/c mice were immunized intradermally then challenged with an aerosol of SCHU S4 six weeks later. Changes in the
levels of a selected panel of cytokines and chemokines were examined in the lungs, spleens, and sera of vaccinated and
challenged mice. Mostly, increased cytokine and chemokine levels correlated with increased bacterial burden. However,
after adjusting for this variable, immunization with either of the two Schu S4 mutants resulted in higher levels of several
pulmonary cytokines, versus those resulting after LVS immunization, including IL-17. Moreover, treatment of mice
immunized with DclpB with anti-IL-17 antibodies post-challenge enhanced lung infection.
Conclusions/Significance: This is the first report characterizing local and systemic cytokine and chemokine responses in
mice immunized with vaccines with different efficacies against aerosol challenge with virulent F. tularensis subsp. tularensis.
It shows that increases in the levels of most of these immunomodulators, including those known to be critical for protective
immunity, do not superficially correlate with protection unless adjusted for the effects of bacterial burden. Additionally,
several cytokines were selectively suppressed in the lungs of naı ¨ve mice, suggesting that one mechanism of vaccine action
is to overcome this pathogen-induced immunosuppression.
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Introduction
Typhoidal tularemia initiated by inhalation of Francisella
tularensis subsp. tularensis had an historical mortality rate of
.50% prior to the advent of chemotherapy [1]. This coupled
with its low inhaled infectious dose (10 CFU or less) led to F.
tularensis subsp. tularensis being developed as an aerosolizable
biological warfare agent during World War II and the Cold War.
To counter this threat, the US Army developed a live vaccine
strain, F. tularensis LVS, from an attenuated Russian strain derived
from the less virulent subsp. holarctica [1]. In human volunteer
studies LVS administered by scarification was shown to be 25–
100% effective against aerosol challenge and 66–90% effective
against intradermal (ID) challenge with F. tularensis subsp. tularensis
strain SCHU S4 [2,3,4]. Efficacy appeared to be dependent on the
vaccine and challenge doses, and on the intervening period
between vaccination and challenge. Efficacy was defined as an
absence of disease symptoms following challenge, the appearance
of which automatically led to treatment with antibiotics. Hence,
many of the adjudged vaccine failures in these studies might well
have survived an otherwise lethal challenge. Serological assays on
volunteers post-vaccination, failed to establish a correlation
between antibody agglutination titre and protection from disease
symptoms [5]. The absence of a correlate of protection, coupled
with regulatory concerns over its method of manufacture and
attenuation has prevented the licensure of LVS for general use.
Modern technical approaches might be able to overcome these
issues.
Nevertheless, it might be possible to make an improved novel
vaccine, especially against airborne challenge. To this end we have
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SCHU S4 to serve this purpose, not least because they express
antigens unique to subsp. tularensis that might contribute
significantly to protective immunity. However, due to the dearth
of natural human tularemia infections initiated by inhaling subsp.
tularensis, novel vaccines will need to be tested according to the
FDA Animal Rule to gain regulatory approval (http://www.fda.
gov/cber/rules/humeffic.htm). The Animal Rule allows for
efficacy testing of a vaccine to be performed exclusively using
relevant animal models of tularemia provided that its mechanism
of action in such models predicts its efficacy in humans. Given that
protection itself remains the sole evidence of LVS efficacy in
humans, it seems reasonable to begin looking for correlates of
protection in vaccinated and challenged hosts, in the hope that this
will indicate candidate correlates in unchallenged vaccinees.
Mouse models have been the mainstay of F. tularensis infection
and immunity research for the past quarter century [6]. The major
perceived weakness of these models is their relatively high
susceptibility to airborne versus systemic challenge with subsp.
tularensis following systemic immunization with LVS. However,
this provides a sensitive means for comparing the relative efficacy
against inhalation tularemia of novel vaccines versus LVS, the
current gold standard. In mice, LVS-elicited immunity to systemic
or respiratory challenge with subsp. tularensis is known to be
critically dependent on the actions of interferon gamma (IFNc)
and CD4
+ and CD8
+ T cells [7,8,9]. Francisella-specific CD4
+ and
CD8
+ T cells persist for prolonged periods in the circulation of
humans immunized with LVS or convalescent patients, and
secrete IFNc when re-stimulated with specific antigens
[10,11,12,13,14,15]. Additionally, early molecular and cellular
events following LVS vaccination of humans has recently been
documented [16,17]. However, none of the aforementioned
immune responses have been correlated to protection in humans
since no challenge studies were performed. In this regard, LVS is
effective in BALB/c, but not C57BL/6 mice despite the fact that
both generate pathogen-specific cell-mediated immune responses
following vaccination [8,18,19,20]. Thus, the mere generation of
IFNc-producing T cells appears to be an insufficient criterion for
predicting LVS efficacy in mice, and possibly humans.
Recently, we showed that mutant strains of SCHU S4, missing
either the clpB gene or both the fupA (FTT0918) and capB genes
were at least as attenuated as LVS, but afforded better protection
against an aerosol challenge with wild-type SCHU S4 in a murine
model, significantly so in the case of DclpB [21]. In the present
study we have vaccinated mice with either of these mutants or
LVS and compared a selection of molecular immune responses in
the lungs, spleen, and serum following aerosol challenge with
SCHU S4 in an effort to reveal potential correlates of protection.
The results showed that mice immunized with either of the SCHU
S4-based mutants produced significantly more IL-17 and
contained fewer bacteria in the lungs than mice immunized with
LVS by day 7 of infection. No other cytokine or chemokine
showed such a straightforward inverse correlation with lung
bacterial burden. However, when the latter variable was adjusted
for, several other cytokines and chemokines were expressed at
relatively higher levels in mice immunized with DclpB or
DfupADcapB. Treating immunized mice with anti-IL-17 mabs,
reduced pulmonary IL-17 levels and increased the lung bacterial
burden. No useful correlates of protection were observed in the
serum. Compared to immunized mice, several lung cytokine
responses appeared to be suppressed in naı ¨ve mice, whereas in the
serum many of the same molecules were found at higher levels in
the latter versus former mice. The consequences of these findings
for future vaccine development are discussed.
Results
Efficacy of SCHU S4 mutants versus LVS against aerosol
challenge
Throughout the results section all references to differences being
significant indicate statistically significant differences at P,0.05 or
P,0.0045 (to account for mass significance) by the tests stated in
materials and methods. Previously we showed that mice
immunized ID with 10
5 CFU of DclpB were significantly better
protected than LVS immunized mice against a subsequent aerosol
challenge with SCHU S4 [21]. Protection in mice immunized with
DfupADcapB was intermediate between the former two groups, but
this was not significant in either comparison. In the present study,
similarly immunized mice were challenged along with naı ¨ve mice
six weeks later with a low dose aerosol of SCHU S4. Surviving
mice were killed on the stated days post-infection for bacteriology.
The course of infection in each of the four groups is shown by
figure 1. By day 4 of infection, all immunized groups harbored
significantly fewer bacteria in their lungs than naı ¨ve mice, and
lung burdens in mice immunized with DclpB were significantly
lower than in mice immunized with DfupADcapB. All vaccinated
groups contained significantly fewer bacteria than naive mice in
their livers and spleens at this time. The liver and spleen burden in
mice immunized with DclpB was significantly lower than in mice
immunized with LVS at this time. All remaining naı ¨ve mice were
dead by day 5 of infection. By day 7 of challenge, mice immunized
with DclpB contained significantly fewer bacteria in all organs
compared to mice immunized with LVS. None of the latter mice
survived to day 10 by which time there was no significant
difference in the bacterial burdens in mice immunized with
DfupADcapB or DclpB. Between days 7–10, bacterial burdens
decreased somewhat in the organs of both groups. However,
between days 10–14, bacterial burdens increased in all organs in
mice immunized with DfupADcapB, but decreased further in all
organs in mice immunized with DclpB, and the burdens in each
organ were significantly different between these two groups at this
time. No mice immunized with DfupADcapB survived to day 18, by
which time surviving mice immunized with DclpB were continuing
to resolve infection in all organs. All groups of immunized mice
Figure 1. Course of infection in mice immunized ID with
10
5 CFU of SCHU S4-based mutants DfupADcapB (red), DclpB
(blue), LVS (green) and in naı ¨ve mice (black) following aerosol
challenge at six weeks post vaccination.
doi:10.1371/journal.pone.0013349.g001
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with progressive primary tularemia. We have obtained similar
results previously [21].
Additional experiments showed that mice immunized ID with
either LVS or clpB survived ID challenge with 100,000 CFU of
SCHU S4 (not shown). However, the latter mice were significantly
better protected than LVS-immunized mice against IN challenge
with 10, 100, or 1000 CFU of SCHU S4 (figure 2). The IN route
was chosen for this experiment because it allowed more precision
with the delivered doses of SCHU S4 than did aerosol exposure.
Changes in lung cytokine and chemokine levels post-
challenge
Changes in the levels of 21 selected cytokines and chemokines
were monitored in the immunized and challenged mice shown in
figure 1. Differences between comparison groups were considered
to be significant at P,0.05 or P,0.0045 as appropriate. The most
pronounced changes in the lungs are shown in figure 3. By day 2
of infection, significant fold increases above background in the
mean levels of IL-6 (40–55-fold), IL-17 (9–14-fold), KC (8–11-
fold), MCP-1 (10–14-fold), and RANTES (2–4-fold) were observed
in lung homogenates from all vaccinated groups, but not
unvaccinated control mice. Additionally, levels of IFNc (8–19-
fold) and TNFa (3-fold) were significantly above normal in mice
immunized with DfupADcapB or DclpB at this time. IL-1b (9–10-
fold) levels were significantly depressed in naı ¨ve and LVS-
immunized mice by day 2 of infection.
By day 4 of infection, levels of IL-6 (180–345-fold), KC (28–98-
fold), MCP-1 (35–280-fold), and RANTES (2–9-fold) were
significantly above background in all challenge groups. IFNc
(102–540-fold) was only elevated in the immunized groups.
Between the infected groups MCP-1 (280-fold versus 35–55-fold)
and KC (98-fold versus 28–55-fold) levels were significantly higher
in the control versus any of the immunized groups at this time. In
contrast, IFNc (102–540-fold versus 3-fold), IL-17 (110–180-fold
versus 3-fold), IL-1a (10–20-fold versus 3-fold), RANTES (3–9-
fold versus 2-fold), and TNFa (8–23-fold versus 2-fold) levels were
significantly higher in immunized versus control mice. Among the
immunized groups, RANTES levels were significantly greater in
mice immunized with DclpB versus the other vaccine strains (9-fold
versus 3–6-fold), TNFa levels were significantly greater in mice
immunized with DfupADcapB (23-fold versus 8–9-fold). GM-CSF
(11-fold) and IL-3 (4-fold) levels were significantly higher than
normal only in mice immunized with DfupADcapB. IL-1b levels
were significantly increased (4-fold) only in mice immunized with
DclpB or DfupADcapB.
All control mice were dead by day 7 of infection, by which time
all three surviving vaccinated groups showed a further increase
over background in levels of IFNc (3000–6800-fold), TNFa (55–
105-fold), IL-1a (65–72-fold), IL-1b (10–14-fold), IL-3 (4–9-fold),
IL-6 (1200–1900-fold), KC (91–156-fold), MCP-1 (71–296-fold),
RANTES (20-fold), and GM-CSF (9–23-fold). In contrast, IL-17
levels rose in mice immunized with DfupADcapB (355-fold above
background) or DclpB (475-fold above background), but fell in
mice immunized with LVS (94-fold above background). Levels of
IL-12p40 were significantly depressed (5-fold) in LVS-immunized
mice at this time, but were at normal levels in the other two groups
of vaccinated mice, and hence do not provide a useful correlate of
protection. No LVS-immunized mice survived to day 10 of
infection. By this time most cytokines and chemokines had fallen
markedly from their day 7 peaks, but remained significantly above
background levels in the two surviving groups of mice. Notable
exceptions were IL-1a, IL-1b and RANTES which remained at
similar levels to day 7. Between the two surviving groups, there
were no significant differences in the levels of any cytokine or
chemokine at this time. By day 14 of infection, most cytokines and
chemokines were declining towards background in surviving mice
immunized with DclpB, whereas the opposite trend was observed
for mice immunized with DfupADcapB. In particular, levels of
IFNc, IL-1a, Il-1b, IL-6, KC, MCP-1, MIP-1b, RANTES, and
TNFa were significantly greater in mice immunized with
DfupADcapB versus DclpB at this time. On the other hand, IL-1a,
IL-3,and IL-17 levels declined in both groups between days 10 and
14. By day 18, IL-1a (7-fold), IL-6 (24-fold), KC (6-fold), MCP-1
(7-fold), and RANTES (15-fold) remained significantly elevated in
the surviving DclpB-vaccinated mice.
In the lung, the majority of the cytokines were strongly
correlated with bacterial load (Table 1). This suggests that
cytokine levels, at least at a relatively early stage of infection (4–
7 days), are affected by the bacterial burden. In an attempt to
determine the effect of this variable on the molecular immune
responses elicited by the three vaccine strains, the cytokine levels
were modeled using ANOVA with bacterial load and immuniza-
tion type as explanatory variables.
For the cytokines IFN-c, IL-10, IL-12-p40, IL-1a, IL-1b, IL-2,
KC, RANTES and TNFa, the effect of the immunizing strain was
significant. The DclpB mutant had the highest cytokine levels
(after removing the effect of the bacterial load) followed by
DfupADcapB and LVS. The difference between DclpB and
DfupADcapB was significant for IL-12-p40 and RANTES, the
difference between DclpB and LVS was significant for all the
selected cytokines and the difference between DfupADcapB and
LVS was significant for IL-10, IL-2 and KC. In addition, pair wise
analysis on IL-17 and IL-6 were made and significant differences
between DclpB and LVS were observed. The complete results are
presented in Table 1.
Figure 2. Survival of control mice (black) or mice immunized ID with LVS (green) or DclpB (blue) following IN challenge with
different doses of SCHU S4 six weeks post vaccination. Blue asterisk, significantly greater survival than control mice or mice immunized with
LVS; green asterisk, significantly greater survival than control mice.
doi:10.1371/journal.pone.0013349.g002
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challenge
The most pronounced changes in cytokine and chemokine levels
in the spleen are shown in figure 4. In the spleen by day 2 of
infection, KC levels were significantly (P,0.05) above background
(3-fold) in immunized mice only. IL-1b levels were significantly
depressed (3–6-fold) in mice immunized with LVS and naı ¨ve mice at
this time. By day 4, levels of IL-1a (2.5–7.5-fold), IL-6 (5–4000-fold),
and KC (6–365-fold) were significantly above normal in all four
groups. IFNc was significantly above normal in naı ¨ve mice (550-
fold), and mice immunized with DfupADcapB (48-fold), or LVS (33-
fold), but not in mice immunized with DclpB (3-fold); the levels in
naı ¨ve mice were significantly higher than in any of the immunized
mice. Levels of IL-6 (4000-fold versus 5–28-fold), and KC (365-fold
versus 6–11-fold) were also significantly higher in naı ¨ve mice than in
immunized mice at this time. Moreover, IL-17 (33-fold), MCP-1
(1830-fold), MIP-1b (15-fold), and TNFa (17-fold) were only
significantly above background in naı ¨ve mice at this time. Amongst
the immunized groups, IFNc levelsweresignificantly higherinLVS-
(33-fold) and DfupADcapB- (48-fold) than in DclpB- (3-fold) immu-
nized mice, and IL-6 levels were significantly higher in LVS- (28-
fold) versus DclpB- (5.5-fold) immunized mice. By day 7, levels of IL-
1a (4–7-fold), IL-6 (17–90-fold) and KC (20–30-fold) were
significantly elevated in all three groups of vaccinated mice whereas,
IL-1b (3–4-fold), IFNc (26-fold), TNFa (5-fold), MIP-1b (2-fold),and
MCP-1 (5–6-fold) levels were only elevated in mice immunized with
LVS or DfupADcapB, and only the latter group exhibited an increase
inIL-17(5-fold).Byday10, IL-1a (6–8-fold),IL-6 (56–128-fold),KC
(13–23-fold), were significantly elevated in both groups of surviving
mice, whereas IL-1b (5-fold), IFNc (75-fold), IL-17 (8-fold), TNFa
Figure 3. Changes in pulmonary cytokine and chemokine levels in naı ¨ve mice (black) and mice immunized ID with 10
5 CFU of LVS
(green), DclpB (blue), or DfupADcapB (red) then challenged by aerosol six weeks later with SCHU S4. Dashed horizontal line = mean
background level.
doi:10.1371/journal.pone.0013349.g003
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significantly elevated in mice immunized with DfupADcapB.B yd a y
14, IL-1a (4–13-fold), IL-6 (50-fold), KC (6–17-fold) levels were
significantly elevated in both surviving vaccine groups, whereas
IFNc (25-fold), IL-1b (5-fold),MIP-1b (9-fold), TNFa (7-fold), MCP-
1 (15-fold), were only elevated in mice immunized with DfupADcapB.
By day 18, IL-6 (15-fold) and KC (4-fold), were significantly above
background in surviving DclpB- immunized mice.
Changes in serum cytokine and chemokine levels post-
challenge
The most pronounced changes in serum cytokine and
chemokine levels are shown in figure 5. Compared to sera from
unchallenged control mice, serum levels of IFNc (mean 7–21-fold
increase), IL-6 (20–40-fold increase), and IL-17 (mean 8–12—fold
increase) levels were significantly raised in immunized, but not un-
immunized mice on day 2 of infection. Additionally, serum IL-2
levels were significantly above normal in mice immunized with
DfupADcapB (3-fold) at this time. By day 4, there was a further
significant increase over background levels of IFNc (50–180-fold),
IL-6 (280–410-fold), and IL-17 (40–165-fold) in all three
vaccinated groups. However, by this time the mean change in
the level of IFNc (335-fold) and IL-6 (3,400-fold) was greater in
naı ¨ve versus any of the vaccinated groups; this difference was
statistically significant for IL-6. IL-17 levels were also elevated in
naı ¨ve mice at this time (17-fold), but not by as much as in
vaccinated mice. KC levels were significantly above normal in all
groups at this time (mean 10–125-fold). As at day 2 of infection,
IL-2 levels were significantly higher than normal in mice
immunized with DfupADcapB (5-fold) as well as in mice immunized
with LVS (6-fold). Furthermore, levels of IFNc were significantly
greater in these two groups than in mice immunized with DclpB at
this time. TNFa (3–10-fold) levels were significantly above
background in all groups except mice immunized with DclpB at
this time. By day 7 of infection, levels of IFNc (90–250-fold), IL-6
(360–390-fold), IL-17 (30–75-fold), KC (20–35-fold), TNFa (5–13-
fold), and IL-2 (2–3.5 fold) were significantly elevated above
background in all three vaccinated groups. By day 10 post-
challenge, levels of IFNc (57–61-fold), IL-6 (99–132-fold), IL-17
(27–59-fold), TNFa (5–7-fold) and KC (12-fold) remained
significantly above normal in both remaining groups of vaccinated
mice. By day 14, IL-6 remained significantly above normal in both
groups of immunized mice (10–550-fold) whereas IFNc (150-fold),
KC (10-fold), RANTES (7-fold), and TNFa (26-fold) were
significantly above normal only in mice immunized with
DfupADcapB. By day 18, only IL-6 levels (8-fold) were significantly
above background in surviving mice immunized with DclpB.W e
have previously reported the same pattern of responses for naı ¨ve
BALB/c mice challenged by aerosol with SCHU S4 [22].
A putative role for IL-17 in pulmonary protection
The above cytokine and chemokine analyses showed that IL-17
level in the lungs on day 7 post-challenge was the main immune
mediator that correlated with the superior efficacy of the SCHU
S4 mutants versus LVS (figure 3). To determine whether IL-17
might be contributing to enhanced protection, mice immunized
with DclpB, then challenged IN 6 weeks later with 100 CFU of
SCHU S4 were treated with two anti-IL-17 mabs. This challenge
regimen was chosen because it is appeared to be close to the
threshold of the protective immune response (figure 2), and hence
most likely to reveal any detrimental effects. In a preliminary
experiment treatment at 2 h, 3 days and 7 days of such mice with
the anti-IL-17A mab from R&D Systems had no effect on survival
(not shown). Therefore, in a similar experiment some mice were
treated on days 4, 5, 6, post-challenge with a combination of this
mab and another anti-IL-17A mab from eBiosciences, or the
corresponding isotype controls, and some were untreated. In this
case, treatment was administered during the period of onset of
pulmonary IL-17 production (figure 3) in the hope that this would
achieve maximal effect. On day 7 post-challenge 5 mice/group
were killed and organ bacterial burdens and lung cytokine levels
determined (Table 2). Mice treated with anti-IL-17 mabs had a
mean 3-fold reduction in IL-17 levels and a mean 10-fold increase
in lung bacterial burden compared to the control groups, but these
differences were not statistically significant. Moreover, IL-17 levels
were still 50-fold above background in the mice treated with anti-
IL-17 mabs. In keeping with the increased bacterial burden, mice
treated with anti-IL-17 mabs had ,3-fold more IFNc in their
lungs than the control groups, but this difference was not
statistically significant. Mice not killed on day 7 were monitored
for survival for 28 days post-challenge, and 1/5 untreated mice
and 1/5 mice treated with anti-IL-17 mabs died during this time.
Histopathology of pulmonary tularemia in mice
immunized with DclpB or LVS
A histological examination of the lungs on day 7 post challenge
showed medium to large foci of consolidations remain easily visible
Table 1. The influence of immunization with DfupADcapB (A),
DclpB (B) or LVS (C) on pulmonary cytokine levels following
aerosol challenge with SCHU S4.
ANOVA
p-values
Pair wise comparisons
p-values
Cytokine Cor Imm CFU A vs. B A vs. C B vs. C
GM-CSF 0,86 0,0328 0,0000 0,2519 0,0090 0,1134
IFNc 0,84* 0,0013* 0,0000* 0,1871* 0,0092* 0,0004**
IL-10 0,56* 0,0004* 0,0004* 0,0761* 0,0012** 0,0001**
IL-12p40 20,11* 0,0000* 0.2413* 0,0031** 0,0071* 0,0000**
IL-12p70 20,54 0,2886 0,0579 0,1074 0,5603 0,2055
IL-17 0,20 0,0116 0.1465 0,5017 0,0095 0,0042**
IL-1a 0,76* 0,0005* 0,0000* 0,0344* 0,0103* 0,0000**
IL-1b 0,74* 0,0003* 0,0000* 0,0076* 0,0152* 0,0000**
IL-2 0,67* 0,0000* 0,0000* 0,5724* 0,0001** 0,0000**
IL-3 0,90 0,0516 0,0000 0,2469 0,0923 0,0116
IL-4 0,80 0,8098 0,0000 0,4194 0,7683 0,7010
IL-6 0,72 0,0035 0,0000 0,1812 0,0216 0,0001**
IL-9 0,37 0,0453 0.0343 0,1902 0,0171 0,1712
KC 0,89* 0,0015* 0,0000* 0,9676* 0,0014** 0,0039**
MCP-1 0,88 0,8857 0,0000 0,9629 0,6425 0,6721
MIP-1b 0,90 0,7349 0,0000 0,2139 0,9533 0,5242
RANTES 0,55* 0,0004* 0,0049* 0,0004** 0,0887* 0,0001**
TNFa 0,86* 0,0005* 0,0000* 0,0536* 0,0078* 0,0001**
VEGF 20,90 0,1272 0,0000 0,0360 0,4712 0,1007
The analysis is based on lung data from day 4 and 7. The correlation between
cytokine levels and bacterial load are presented in column 1. The cytokine levels
were modeled using ANOVA with the bacterial load (CFU) and the
immunization (Imm) as explanatory variables; their corresponding P values are
presented in columns 2 and 3. Cytokines significantly affected by the vaccines
are highlighted by a single asterisk. The mean effects, after removing the affect
of the bacterial load, are presented in columns 4–6. P values for the pair-wise
comparisons are presented in columns 7–9 and significant findings are
highlighted by a double asterisk.
doi:10.1371/journal.pone.0013349.t001
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spaces in these affected areas are filled with large numbers of intact
and degenerated neutrophils admixed with small numbers of
mononuclear cells (Fig. 7). In contrast, inflammation was less
widespread in the lungs of the mice immunized with DclpB and
consisted mainly of mononuclear cells.
Discussion
The development of facile correlates of protection assays will
facilitate the approval of tularemia vaccines for clinical use under
the FDA Animal Rule. In mouse models of tularemia, highly
attenuated LVS given ID protects against .1000 LD50 ID
challenge with wild-type F. tularensis subsp. tularensis, but only
prolongs life by a few days against a low dose aerosol challenge
[8,18]. A similar relative efficacy difference has also been shown
for humans [2,3]. More recently, Fischer rats immunized with
LVS were shown to resist respiratory challenge with up to
10
8 CFU of SCHU S4 [23].This appears to be a 10,000-fold
higher challenge dose than the breakthrough dose for LVS-
immunized humans [4]. Thus, it appears that LVS-elicited
protection is exaggerated in rats, but understated in mice,
compared to humans. It is possible that vaccines that perform
better than LVS in mice will also do so in humans. In contrast, it
seems unlikely that anything can be shown to be substantially
superior to LVS in the Fischer rat model. Recently, we showed
that deleting either the heat shock gene, clpB, alone, or the iron-
acquisition gene, fupA, and putative capsule gene, capB, together,
created highly attenuated mutant strains of F. tularensis subsp.
tularensis strain SCHU S4. When administered ID to BALB/c mice
the SCHU S4 deletion mutants provided better protection than
LVS against a subsequent low dose aerosol challenge with the
wild-type strain [21]. This finding was confirmed in the present
study and was extended by showing that mice immunized with
DclpB were significantly better protected than LVS-immunized
mice following respiratory challenge with up to 10
3 CFU of
SCHU S4.
Additionally, herein we have compared global molecular
immune responses in mice vaccinated with one or other
attenuated strain and challenged with an aerosol of SCHU S4
in an attempt to establish a correlate of protection. Several
cytokines were found at higher levels in the lungs of immunized
versus naı ¨ve mice, but amongst the immunized groups, there was
little direct correlation between pulmonary cytokine levels and
protective efficacy. Instead, they mostly rose in response to
increasing bacterial burden.
Amongst all of the pulmonary cytokines and chemokines
examined, peak levels of pulmonary IL-17 that occurred on day
7 of infection provided the most straightforward potential correlate
of protection. By this time, significantly greater levels (4–5-fold) of
Figure 4. Changes in splenic cytokine and chemokine levels in naı ¨ve mice (black) and mice immunized ID with 10
5 CFU of LVS
(green), DclpB (blue), or DfupADcapB (red) then challenged by aerosol six weeks later with SCHU S4. Dashed horizontal line = mean
background level.
doi:10.1371/journal.pone.0013349.g004
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the SCHU S4-based vaccines versus LVS, despite the fact that
pathogen burden in this organ was 10-fold greater in the latter
versus former groups. Interestingly, reducing IL-17 levels in the
lungs of mice immunized with DclpB by 3-fold, also caused a 10-
fold increase in bacterial burden by day 7 of infection.
Additionally, IL-12p40 levels were significantly depressed in
LVS-immunized mice at this time, and IL-12p40 levels have
been shown to be co-dependent on IL-17 levels during primary
pulmonary infection of mice with LVS[24,25]. However, as
unadjusted pulmonary IL-12p40 levels bacteria remained at
normal levels in mice immunized with the SCHU S4 mutants,
this cannot function as a straightforward correlate of protection.
When adjusted for the effects of the different bacterial burdens,
several additional cytokines and chemokines were present at
relatively higher levels in the lungs of the mice immunized with
DclpB, and to a lesser extent, in the lungs of mice immunized with
DfupADcapB, than in the lungs of mice immunized with LVS. This
could help explain the apparent paradox of having greater total
amounts of IFN-c in the lungs of the mice immunized with LVS
versus the other two vaccine strains on day 7 of infection, given that
thiscytokineiscriticalfortheexpressionofanti-Francisellaimmunity.
After day 7, IL-17 levels declined in the surviving mice
immunized with either of the SCHU S4 mutants even as bacterial
burden rose in the lungs of mice immunized with DfupADcapB.I n
contrast, pulmonary IFN-c levels rose in the latter mice in
response to recrudescent infection. This suggests that IL-17 and
IFNc arose from different sources or were under different feedback
control.
Many of the same cytokine and chemokine expression patterns
were observed in the spleens of immunized mice, but were
Figure 5. Changes in serum cytokine and chemokine levels in naı ¨ve mice (black) and mice immunized ID with 10
5 CFU of LVS
(green), clpB (blue), or DfupADcapB (red) then challenged by aerosol six weeks later with SCHU S4. Dashed horizontal line = mean
background level.
doi:10.1371/journal.pone.0013349.g005
Table 2. Effect of anti-IL-17 MAb treatment on infection in
mice immunized with DclpB.
Vaccinated
mice treatment
Log10 lung
bacteria
± SEM
Lung IL-17
levels ± SEM
(pg/ml)
Lung IFNc
levels pg/ml
± SEM
anti-IL-17 mabs 6.160.58 80.3627.8 314861326
isotype matched mabs 5.160.61 241.8678.3 12616960
Untreated 5.260.88 215.1668.2 10816612
Untreated and uninfected 1.560.3 1.860.003
Mice (n=5/group) immunized intradermally with 10
5 CFU of DclpB were
challenged 6 weeks later IN with 100 CFU of SCHU S4. Antibodies were
administered IP on days 4, 5, 6 post challenge.
doi:10.1371/journal.pone.0013349.t002
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immunized with DclpB. However, there were approximately 100-
fold fewer bacteria in the spleens versus the lungs on any given day
of infection. In this light, relative amounts of some cytokines and
chemokines were similar or higher in the former organ, especially
in naı ¨ve mice. In particular, this further emphasizes the presence
of high levels of IFNc, TNFa, IL-1a, IL-17, and MIP-1b, evident
in the spleens versus the lungs of naı ¨ve infected mice. This finding
is in keeping with that of others showing that pulmonary immune
responses are suppressed in naı ¨ve mice challenged by aerosol with
SCHU S4 [26] On the other hand, KC levels were highest in the
lungs of naı ¨ve mice on day 4 of infection suggesting some degree of
selectivity to the pulmonary immunosuppression.
Changes in absolute cytokine and chemokine levels in the serum
did not fully reflect the changes observed in the lungs or spleen. In
particular, the dramatic increases in IL-1a levels seen in the lungs,
and to a lesser extent in the spleens, were not observed in the serum.
Relative differences in serum IL-17 levels among the immunized
groups were the same as those observed in the lungs on day 7, but
were less obvious. Moreover, there was a temporal component to
this, since mice immunized with DclpB had significantly lower levels
of serum IL-17 than the two other vaccinated groups on day 4 of
infection. On the other hand, the increases observed in the spleens,
but not the lungs of naı ¨ve mice in IFNc, IL-6, and TNFa, were
recapitulated in the serum. Because bacteremia was not universally
present, it was not possible to determine the effect of this variable on
Figure 6. Histopathology of pulmonary tularemia in mice immunized with DclpB or LVS. Medium to large foci of lung consolidations
(arrows) were seen in all LVS-immunized mice at day 7 post challenge, but only occasionally in clpB-immunized mice. Each photograph was taken
from individual mice.
doi:10.1371/journal.pone.0013349.g006
Figure 7. Histopathology of pulmonary tularemia in mice immunized with DclpB or LVS. left: The lung from an LVS-immunized mouse
killed at day 7 post challenge showing severe subacute bronchopneumonia. The alveolar spaces are filled with large numbers of intact and
degenerated neutrophils (arrows) admixed with small numbers of mononuclear cells. (right) the lung from a clpB-immunized mouse killed at day 7
post challenge showing the infiltration of predominantly mononuclear cells (arrowheads) with virtually no neutrophils in the peribronchial area. H&E,
x400.
doi:10.1371/journal.pone.0013349.g007
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and chemokines, remained close to or substantially below
background levels in liver homogenates in this study, suggesting
an assay interference problem.
Although bacterial burden adjustments demonstrated that
relative levels of several pulmonary cytokines and chemokines
were higher in mice immunized with the most protective vaccine
strain versus LVS, such adjustments cannot be extended to
humans. Thus, for practical purposes, only biomarkers that
increase in absolute amounts during a protective immune response
can be used as potential correlates of protection. In this regard,
enhanced absolute IL-17 levels in the lungs on day 7 of infection
was the immune mediator that clearly distinguished between mice
immunized with SCHU S4 mutants versus more poorly protected
mice immunized with LVS.
Several other groups have recently shown that IL-17 is critical
for controlling primary pulmonary infection of mice with LVS
[24,25,27]. They have shown too that multiple types of leukocytes,
including various T cell subsets, produce this cytokine in the lungs
during primary infection. In particular, CD4
+, CD8
+ and
CD4
2CD8
2 T cells induced by IN vaccination were all able to
activate macrophages in vitro to kill ingested LVS [24]. Moreover,
this immune response is not elicited by ID vaccination with LVS
[24,28]. Given that pulmonary vaccination with LVS generates
better protection than ID vaccination against pulmonary challenge
with clinical strains of subsp. tularensis, it is interesting to speculate
whether this is due to the induction of IL-17 producing T cells by
the former regimen. However, there are a number of caveats to
consider that could render moot such speculation. Firstly, all of the
aforementioned studies with highly attenuated LVS used C57BL/
6 mice that we and others have been unable to protect against
subsp. tularensis challenge [8,18,19]. Secondly, it is not known
whether the aforementioned immune responses persist beyond the
resolution of primary infection. Thirdly, the importance of a
particular immune response for combating primary infection does
not predict its requirement for alleviating secondary infection. For
instance, neutrophils, TNFa and IFNc are far more important for
controlling primary versus secondary LVS infection [29,30].
Fourthly, the importance of a particular host defense in protection
against LVS does not predict its importance in protection against
more virulent strains. For instance, depleting immunocompetent
mice of TNFa, IFNc, or neutrophils renders them much more
susceptible to infection with LVS, but not to virulent subsp.
holarctica or tularensis [31]. Finally, the current study deals with
intradermally vaccinated mice that do not elicit an obvious IL-17
response in the lungs unless subsequently challenged with SCHU
S4. Given these provisos it is clear that a systematic examination of
the cells involved in the control of SCHU S4 infection in the lungs
of BALB/c mice after ID vaccination with DclpB versus LVS will
be required to determine the extent to which they overlap with
cells required to control primary lung infection with attenuated
LVS in C57BL/6 mice. This work is beyond the scope of the
current study.
IL-17 has been shown to participate in host defense against
primary infection with LVS and other intracellular bacterial
pathogens [24,25,27,32,33], and in vaccine-elicited acquired
immunity against tuberculosis [34]. Thus, it would be surprising
if this cytokine did not contribute to some degree to vaccine-
elicited immunity to inhaled F, tularensis regardless of its cellular
source. There are a variety of ways by which IL-17 could
contribute to protection against F. tularensis. For example, IL-17
promotes the production of antimicrobial proteins in the lungs
[35] and the infiltration of other leucocyte populations in this
organ including IFNc-secreting Th1 cells [34] that are known to
be important for combating inhaled F. tularensis. However, the
histological data presented herein clearly shows that the enhanced
levels of IL-17 in the lungs of mice immunized with DclpB versus
LVS does not result in an overall increase in cellular inflammation.
Indeed, in keeping with the lower levels of other proinflammatory
mediators in the lungs such as IL-6 and KC, overt pulmonary
inflammation, especially infiltrating neutrophils is reduced in the
lungs of mice immunized with DclpB versus LVS following
respiratory challenge. It remains to be determined why immuni-
zation with the SCHU S4-based mutants resulted in higher peak
levels of IL-17 in the lungs. This might be revealed by an
examination of the cell-mediated immune responses to vaccination
alone without subsequent challenge, and such studies are planned.
Regardless, of its contribution to anti-Francisella immunity,
absolute changes in IL-17 levels in the sera of immunized and
challenged mice were not sufficient to predict relative efficacy of
the test vaccines with a high degree of confidence which would
seem to rule it out as a target for developing a clinically facile
correlate of protection. Others recently showed that peripheral
blood CD4
+ and CD8
+ T cells from humans immunized with LVS
produced IL-17 upon re-stimulation with a whole cell lysate of
LVS [36]. However, since these individuals were not challenged
with virulent bacteria, and since not all LVS-vaccinated humans
are protected post-immunization [2,3] it is not possible to
determine whether IL-17 served as a correlate of protection in
this situation.
Materials and Methods
Ethics Statement
Mice were maintained and used in accordance with the
recommendations of the Canadian Council on Animal Care
Guide to the Care and Use of Experimental Animals. The work
was approved by the Animal Care Committee of the National
Research Council, Institute for Biological Sciences under protocol
number 2008-06.
Mice
Female BALB/c mice were purchased from Charles Rivers
Laboratories (St. Constant, Quebec) and entered experiments at
8–10 weeks of age.
Bacteria
The ATCC isolate 29684 of LVS was used for comparison with
SCHU S4-based vaccines. Wild-type SCHU S4 was obtained from
the Francisella Strain Collection maintained at Umea University,
Sweden. Mutants containing in-frame deletions of the clpB and capB
genes, respectively, of SCHU S4 have been previously described
[21]. The relative efficacies of LVS vs these two mutants against
aerosol challenge with SCHU S4 have been described previously
[21]. For the present study, stock cultures of all strains were
prepared by growing them as confluent lawns on cystine heart agar
supplemented with 1% (w/v) hemoglobin (CHAH). Bacteria were
harvested after 48 h incubation at 37uC into freezing medium
consisting of modified Mueller Hinton broth containing 10% w/v
sucrose. Stocks were aliquoted in a volume of 1 ml and stored at
280uC at a concentration of 10
10–10
11 CFU/ml.
Immunization and challenge
Based on previous findings we chose 10
5 CFU as the ID
immunizing dose for all of the test vaccine strains in the current
study. ID inocula were injected into a fold of skin in the mid-belly
in a volume of 0.05 ml saline. Mice were challenged six-weeks
post-vaccination with SCHU S4. Aerosol challenges were
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as previously described [7,18]. The protocol results in the delivery
of ,20 CFU of SCHU S4 to the lower airways of mice. Intranasal
(IN) challenge was performed on anesthetized mice (10 mlo f
inoculum was administered to each nare followed by an equal
volume of saline). All animal work was performed in a federally-
licensed and Select-Agent-approved small animal containment
level 3 facility. Mice were examined daily for signs of infection and
whenever feasible were euthanized by CO2 asphyxiation as soon
as they displayed signs of irreversible morbidity. Rat anti-mouse
IL-17 monoclonal antibodies (mab) and isotype matched control
antibodies were purchased from R&D Systems (catalog numbers
MAB421 and MAB006), Minneapolis, MN and eBiosciences, San
Diego, CA (catalog numbers 16-7173-85 and 16-4714-85).
Immunized mice received 100 mg of each anti-IL-17 mab, or
each control mab IP on days 4,5,6 post-challenge. Used singly,
both antibodies have been shown to partially abrogate immune
responses in a variety of disease models [37,38,39,40].
Bacteriology and cytokine assays
On the stated days post-challenge, some mice (n=4/group)
were killed and blood for serum was collected by cardiac puncture.
For bacteriology, an aliquot of whole blood was diluted in nine
volumes of sterile water to lyse host cells. The lungs, spleens, and
livers were removed and homogenized in the presence of protease
inhibitors (Complete Protease Inhibitor Cocktail Tablets, Roche
Applied Sciences, Laval, Quebec), then placed on ice. Homoge-
nates were diluted in saline and plated on CHAH agar.
Thereafter, homogenates were clarified by centrifugation and
the supernatants were filtered through a 0.22 mm membrane and
then plated to confirm their sterility. Serum was similarly
sterilized, and all samples were stored frozen at 220uC until
needed. Preliminary studies demonstrated that the protease
inhibitors had no effect on the recovery of viable bacteria. Levels
of cytokines and chemokines were determined using BeadlyteH
Mouse 21-plex Cytokine Detection System on a LuminexH 100 IS
system (Luminex, Austin, TX). Serum samples (25 ml) were diluted
1:2 and organ homogenates were used neat and analyzed as
specified by the manufacturer. The cytokine/chemokine concen-
trations were calculated against the standards using BeadviewH
software version 1.03 (Upstate).
Histology
Lungs were harvested en bloc into 10% buffered formalin and
processed by standard pafaffin embedding techniques. Sections
were cut at 4 mm, stained with hematoxylin and eosin and
examined by light microscopy.
Statistical analysis
Differences among the groups in the levels of bacteria and
cytokines and chemokines were separately compared statistically
by ANOVA with Dunnett’s or Tukey’s post-hoc test, or by t test as
appropriate on log transformed data using GraphPad PrizmH
version 4.0 software. Differences were considered to be statistically
significant when P,0.05.
The above analyses do not take into account that cytokines
levels may be directly affected by the levels of bacteria. Therefore,
an additional complementing analysis was performed. Here the
cytokine levels (log10-transformed) were modeled using an
ANOVA with bacterial load (log10 CFU) and vaccine type
(LVS, DclpB mutant or DfupADcapB mutant) as explanatory
variables. For this purpose we used data from lung samples
collected on day 4 and 7. This model allows us to compare the
effects of the immunizations after that the influence of the bacterial
load has been removed. Data from 19 cytokines were modeled (IL-
13 and IL-5 were not modeled due to low quality data). The
immunizations that had a statistically significant (Bonferroni
corrected P,0.05, i.e. P,0.05/19) effect on the cytokines levels
were studied further by performing pair-wise differences between
the immunizations. The estimated affect of the bacterial load were
removed from the cytokines levels and the residuals were used to
compare all pairs of immunizations using Welch’s t test. Pair-wise
differences were considered to be statistically significant when the
Bonferroni corrected P,0.05, i.e. P,0.05/11.
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